The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability

[1]  Z. Dong,et al.  BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression , 2021, Oncogene.

[2]  L. Bullinger,et al.  Precision medicine in myeloid malignancies. , 2021, Seminars in cancer biology.

[3]  Lei Jiang,et al.  R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis. , 2021, Molecular cell.

[4]  A. Mead,et al.  The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function , 2020, The Journal of experimental medicine.

[5]  Ping Zhang,et al.  Clusterization in acute myeloid leukemia based on prognostic alternative splicing signature to reveal the clinical characteristics in the bone marrow microenvironment , 2020, Cell & bioscience.

[6]  B. Ebert,et al.  CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia , 2020, Cell reports.

[7]  Yue Huang,et al.  Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. , 2020, Cancer cell.

[8]  Chuan He,et al.  RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia. , 2020, Cell stem cell.

[9]  Shaoguang Li,et al.  Leukemogenic Chromatin Alterations Promote AML Leukemia Stem Cells via a KDM4C-ALKBH5-AXL Signaling Axis. , 2020, Cell stem cell.

[10]  Ping Zhang,et al.  Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia , 2020, Therapeutic advances in medical oncology.

[11]  Ze Zhang,et al.  RCC2 contributes to tumor invasion and chemoresistance to cisplatin in hepatocellular carcinoma , 2020, Human Cell.

[12]  Jianjun Chen,et al.  m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. , 2020, Cancer cell.

[13]  M. Hafner,et al.  RNA-binding protein IGF2BP1 maintains leukemia stem cell properties by regulating HOXB4, MYB, and ALDH1A1. , 2019, Leukemia.

[14]  Nan Zhang,et al.  Comprehensive analysis the potential biomarkers for the high-risk of childhood acute myeloid leukemia based on a competing endogenous RNA network. , 2019, Blood cells, molecules & diseases.

[15]  Samie R Jaffrey,et al.  Reading, writing and erasing mRNA methylation , 2019, Nature Reviews Molecular Cell Biology.

[16]  Nan Zhang,et al.  A six-gene-based prognostic model predicts complete remission and overall survival in childhood acute myeloid leukemia , 2019, OncoTargets and therapy.

[17]  D. O’Carroll,et al.  Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia , 2019, Cell stem cell.

[18]  Hualiang Jiang,et al.  Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. , 2019, Cancer cell.

[19]  Wengong Wang,et al.  Loss of YTHDF2-mediated m6A-dependent mRNA clearance facilitates hematopoietic stem cell regeneration , 2018, Cell Research.

[20]  Stefan Hüttelmaier,et al.  Recognition of RNA N6-methyladenosine by IGF2BP Proteins Enhances mRNA Stability and Translation , 2018, Nature Cell Biology.

[21]  James E. Bradner,et al.  R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling , 2018, Cell.

[22]  Shaoyan Hu,et al.  RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation , 2018, BMC Cancer.

[23]  Junwei Shi,et al.  Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control , 2017, Nature.

[24]  Samie R Jaffrey,et al.  Rethinking m6A Readers, Writers, and Erasers. , 2017, Annual review of cell and developmental biology.

[25]  Tao Pan,et al.  Dynamic RNA Modifications in Gene Expression Regulation , 2017, Cell.

[26]  J. Bai,et al.  Overexpression of RCC2 Enhances Cell Motility and Promotes Tumor Metastasis in Lung Adenocarcinoma by Inducing Epithelial–Mesenchymal Transition , 2017, Clinical Cancer Research.

[27]  Chuan He,et al.  m6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program. , 2017, Cancer cell.

[28]  Jie Jin,et al.  FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase. , 2017, Cancer cell.

[29]  Sol Katzman,et al.  RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. , 2016, The Journal of clinical investigation.

[30]  Q. Cui,et al.  SRAMP: prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features , 2016, Nucleic acids research.

[31]  Bas J. Wouters,et al.  Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. , 2016, Blood.

[32]  E. Petricoin,et al.  Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis , 2014, Leukemia.

[33]  Gideon Rechavi,et al.  Gene expression regulation mediated through reversible m6A RNA methylation , 2014, Nature Reviews Genetics.

[34]  Jae Young Lee,et al.  Smad6 inhibits non-canonical TGF-β1 signalling by recruiting the deubiquitinase A20 to TRAF6 , 2013, Nature Communications.